Troubles du rythme: les enseignements des grands essais cliniques, 2004. ,
Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study, European Heart Journal, vol.27, issue.8, pp.949-953, 2006. ,
DOI : 10.1093/eurheartj/ehi825
Epidemiology of atrial fibrillation in France: Extrapolation of international epidemiological data to France and analysis of French hospitalization data, Archives of Cardiovascular Diseases, vol.104, issue.2 ,
DOI : 10.1016/j.acvd.2010.11.012
Atrial Fibrillation: Current Knowledge and Future Directions in Epidemiology and Genomics, Circulation, vol.124, issue.18, pp.1982-1993, 2011. ,
DOI : 10.1161/CIRCULATIONAHA.111.039677
Atrial Fibrillation: A Major Contributor to Stroke in the Elderly, Archives of Internal Medicine, vol.147, issue.9, pp.1561-1564, 1987. ,
DOI : 10.1001/archinte.1987.00370090041008
2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation, Journal of the American College of Cardiology, vol.57, issue.11, pp.101-198, 2006. ,
DOI : 10.1016/j.jacc.2010.09.013
Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham Study, Neurology, vol.77, issue.16, pp.973-977, 1978. ,
DOI : 10.1212/01.wnl.0000407150.80523.a4
Stroke Resulting from Nonvalvular Atrial Fibrillation, Journal of the American Geriatrics Society, vol.8, issue.7, pp.751-757, 1984. ,
DOI : 10.1111/j.1532-5415.1984.tb04175.x
Atrial fibrillation and stroke: new ideas, persisting dilemmas, Stroke, vol.19, issue.8, pp.937-941, 1988. ,
DOI : 10.1161/01.STR.19.8.937
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), Eur. Heart J, vol.31, pp.2369-2429, 2010. ,
2012 Focused Update of the ESC Guidelines for the Management of Atrial Fibrillation, Revista Espa??ola de Cardiolog??a (English Edition), vol.66, issue.1, pp.2719-2747, 2012. ,
DOI : 10.1016/j.rec.2012.11.003
Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin, Circulation, vol.110, issue.16, pp.2287-2292, 2004. ,
DOI : 10.1161/01.CIR.0000145172.55640.93
The role of aspirin for stroke prevention in atrial fibrillation, Nature Reviews Cardiology, vol.27, issue.10, pp.602-606, 2011. ,
DOI : 10.1038/nrcardio.2011.112
Ischaemic stroke and bleeding rates in ???real-world??? atrial fibrillation patients, Thrombosis and Haemostasis, vol.106, issue.1, pp.34-44, 2011. ,
DOI : 10.1160/TH10-10-0674
Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ???real world??? nationwide cohort study, Thrombosis and Haemostasis, vol.106, issue.4, pp.739-749, 2011. ,
DOI : 10.1160/TH11-05-0364
Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation, Annals of Internal Medicine, vol.146, issue.12, pp.857-867, 2007. ,
DOI : 10.7326/0003-4819-146-12-200706190-00007
Systematic Overview of Warfarin and Its Drug and Food Interactions, Archives of Internal Medicine, vol.165, issue.10, pp.1095-1106, 2005. ,
DOI : 10.1001/archinte.165.10.1095
Adherence and Persistence in the Use of Warfarin After Hospital Discharge Among Patients With Heart Failure and Atrial Fibrillation, Journal of Cardiac Failure, vol.20, issue.1, pp.23-30, 2014. ,
DOI : 10.1016/j.cardfail.2013.11.006
One-Year Adherence to Warfarin Treatment for Venous Thromboembolism in High-Risk Patients and Its Association with Long-term Risk of Recurrent Events, Journal of Managed Care Pharmacy, vol.19, issue.4 ,
DOI : 10.18553/jmcp.2013.19.4.291
Factors associated with warfarin discontinuation, including bleeding patterns, in atrial fibrillation patients, Current Medical Research and Opinion, vol.29, issue.7 ,
DOI : 10.1185/03007995.2013.795142
The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics ,
Bleeding During Warfarin and Aspirin Therapy in Patients With Atrial Fibrillation, Archives of Internal Medicine, vol.159, issue.12, pp.1322-1328, 1999. ,
DOI : 10.1001/archinte.159.12.1322
Observations on the Conversion of Prothrombin to Thrombin, Experimental Biology and Medicine, vol.66, issue.1, pp.33-35, 1947. ,
DOI : 10.3181/00379727-66-15973
AN ACCELERATING PROPERTY OF PLASMA FOR THE COAGULATION OF FIBRINOGEN BY THROMBIN 12, Journal of Clinical Investigation, vol.33, issue.8, pp.1175-1182, 1954. ,
DOI : 10.1172/JCI102990
Direct thrombin inhibitors, J. Cardiovasc. Pharmacol. Ther, vol.17, pp.5-11, 2012. ,
Dabigatran versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.361, issue.12 ,
DOI : 10.1056/NEJMoa0905561
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.10 ,
DOI : 10.1056/NEJMoa1009638
URL : https://hal.archives-ouvertes.fr/hal-01038111
Apixaban versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.11 ,
DOI : 10.1056/NEJMoa1107039
The Discovery of Dabigatran Etexilate, Frontiers in Pharmacology, vol.4, p.12, 2013. ,
DOI : 10.3389/fphar.2013.00012
Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study), The American Journal of Cardiology, vol.100, issue.9 ,
DOI : 10.1016/j.amjcard.2007.06.034
Reply to Letters Regarding Article, "Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial", Circulation, vol.125, issue.3, pp.2363-2372, 2011. ,
DOI : 10.1161/CIRCULATIONAHA.111.061721
Dabigatran Association With Higher Risk of Acute Coronary Events, Archives of Internal Medicine, vol.172, issue.5, pp.397-402, 2012. ,
DOI : 10.1001/archinternmed.2011.1666
Meta-Analysis of Randomized Controlled Trials on Risk of Myocardial Infarction from the Use of Oral Direct Thrombin Inhibitors, The American Journal of Cardiology, vol.112, issue.12, pp.1973-1979, 2013. ,
DOI : 10.1016/j.amjcard.2013.08.027
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism, New England Journal of Medicine, vol.368, issue.8, pp.709-718, 2013. ,
DOI : 10.1056/NEJMoa1113697
URL : https://hal.archives-ouvertes.fr/hal-00935796
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial, The Lancet, vol.370, issue.9591, pp.949-956, 2007. ,
DOI : 10.1016/S0140-6736(07)61445-7
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial, Journal of Thrombosis and Haemostasis, vol.5, issue.2, pp.2178-2185, 2007. ,
DOI : 10.1016/S0140-6736(07)61445-7
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism, New England Journal of Medicine, vol.361, issue.24, pp.2342-2352, 2009. ,
DOI : 10.1056/NEJMoa0906598
URL : https://hal.archives-ouvertes.fr/ujm-00439704
Drug Safety and Availability -FDA Drug Safety Communication: Update on the risk for serious bleeding events with the anticoagulant Pradaxa (dabigatran), 2013. ,
Assessment Reinforces Safety Data of Pradaxa® (dabigatran etexilate mesylate), 2013. ,
Dabigatran etexilate mesilate, 2011. ,
A Comparison of Active Adverse Event Surveillance Systems Worldwide, Drug Safety, vol.22, issue.Suppl 1, pp.581-596, 2014. ,
DOI : 10.1007/s40264-014-0194-3
Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis, BMJ, vol.331, issue.7528, pp.1310-1316, 2005. ,
DOI : 10.1136/bmj.331.7528.1310
Comparing Time to Adverse Drug Reaction Signals in a Spontaneous Reporting Database and a Claims Database: A Case Study of Rofecoxib-Induced Myocardial Infarction and Rosiglitazone-Induced Heart Failure Signals in Australia, Drug Safety, vol.62, issue.1, pp.53-64, 2014. ,
DOI : 10.1007/s40264-013-0124-9
Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark, British Journal of Clinical Pharmacology, vol.10, issue.2, pp.173-181, 2002. ,
DOI : 10.1046/j.0306-5251.2001.01220.x
How reimbursement databases can be used to support drug utilisation studies: example using the main French national health insurance system database, European Journal of Clinical Pharmacology, vol.19, issue.3, pp.743-748, 2010. ,
DOI : 10.1007/s00228-010-0819-0
URL : https://hal.archives-ouvertes.fr/hal-00589490
Synthetic Retrospective Studies and Related Topics, Biometrics, vol.29, issue.3, p.479, 1973. ,
DOI : 10.2307/2529171
Methods of Cohort Analysis: Appraisal by Application to Asbestos Mining, Journal of the Royal Statistical Society. Series A (General), vol.140, issue.4, p.469, 1977. ,
DOI : 10.2307/2345280
A Simulation Study of Control Sampling Methods for Nested Case-Control Studies of Genetic and Molecular Biomarkers and Prostate Cancer Progression, Cancer Epidemiology Biomarkers & Prevention, vol.18, issue.3 ,
DOI : 10.1158/1055-9965.EPI-08-0839
A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation, Chest, vol.138, issue.5, pp.1093-1100, 2010. ,
DOI : 10.1378/chest.10-0134
Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke, European Heart Journal, vol.35, issue.4, pp.250-256, 2014. ,
DOI : 10.1093/eurheartj/eht483
Atrial Fibrillation and Outcomes in Heart Failure With Preserved Versus Reduced Left Ventricular Ejection Fraction, Journal of the American Heart Association, vol.2, issue.1, p.5694, 2013. ,
DOI : 10.1161/JAHA.112.005694
Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades, European Heart Journal, vol.27, issue.8, pp.936-941, 2006. ,
DOI : 10.1093/eurheartj/ehi694
CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation, The American Journal of Medicine, vol.127, issue.1, pp.45-52, 2014. ,
DOI : 10.1016/j.amjmed.2013.10.004
Men had a Higher Risk of Recurrent Venous Thromboembolism than Women: A Large Population Study, Gender Medicine, vol.9, issue.1, pp.33-43, 2012. ,
DOI : 10.1016/j.genm.2011.12.002
The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model, Journal of Thrombosis and Haemostasis, vol.94, issue.Suppl. 3, pp.587-594, 2003. ,
DOI : 10.1046/j.1538-7836.2003.00060.x
Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system, Thrombosis and Haemostasis, vol.106, issue.6 ,
DOI : 10.1160/TH11-06-0382
Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction, Journal of Internal Medicine, vol.370, issue.Suppl 1, pp.215-223, 2011. ,
DOI : 10.1111/j.1365-2796.2011.02354.x
Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?, Journal of Thrombosis and Thrombolysis, vol.142, issue.5, pp.295-301, 2013. ,
DOI : 10.1007/s11239-012-0857-9
Portrait de l'usage du dabigatran chez les personnes assurées par le régime public d'assurance médicaments. 56 (Institut national d'excellence en santé et en services sociaux, 2013. ,
Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study, BMJ Open, vol.3, 2013. ,
Bleeding, and Mortality Risks in Elderly Medicare Patients Treated with Dabigatran or Warfarin for Non-Valvular Atrial Fibrillation ,
Pharmacoepidemiological research using French reimbursement databases: yes we can!, Pharmacoepidemiology and Drug Safety, vol.60, issue.Suppl 6, pp.256-265, 2010. ,
DOI : 10.1002/pds.1912
Electronic healthcare databases for active drug safety surveillance: is there enough leverage?, Pharmacoepidemiology and Drug Safety, vol.356, issue.17, pp.611-621, 2012. ,
DOI : 10.1002/pds.3197
Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project, Pharmacoepidemiology and Drug Safety, vol.3, issue.12, pp.1-11, 2011. ,
DOI : 10.1002/pds.2053
The role of databases in drug postmarketing surveillance, Pharmacoepidemiology and Drug Safety, vol.9, issue.5, pp.407-410, 2001. ,
DOI : 10.1002/pds.615
Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?, Pharmacoepidemiology and Drug Safety, vol.15, issue.12, pp.1176-1184, 2009. ,
DOI : 10.1002/pds.1836
Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine clinical practice, Internal Medicine Journal, vol.38, issue.3, pp.261-265, 2014. ,
DOI : 10.1111/imj.12370
Fortnightly review: Adverse drug reactions, BMJ, vol.316, issue.7140, pp.1295-1298, 1998. ,
DOI : 10.1136/bmj.316.7140.1295
URL : http://www.bmj.com/cgi/content/short/316/7140/1295
Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine, British Journal of Clinical Pharmacology, vol.54, issue.2, pp.158-167, 2000. ,
DOI : 10.1046/j.1365-2125.1996.04376.x
Admissions to hospital caused by adverse drug reactions: cross sectional incidence study, BMJ, vol.320, issue.7241, p.1036, 2000. ,
DOI : 10.1136/bmj.320.7241.1036
Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children ??? a prospective observational cohort study of 6,601 admissions, BMC Medicine, vol.7, issue.1 ,
DOI : 10.1371/journal.pone.0046022
Hospital admissions caused by adverse drug events: an Australian prospective study, Australian Health Review, vol.38, issue.1, pp.51-57, 2014. ,
DOI : 10.1071/AH12027
Adverse Drug Reactions Leading to Hospital Admission, Drug Safety, vol.6, issue.6, pp.450-459, 1991. ,
DOI : 10.2165/00002018-199106060-00005
Adverse Drug Events as a Cause of Hospitalization in Older Adults, Drug Safety, vol.15, issue.12 ,
DOI : 10.1007/BF03319101